Literature DB >> 24744772

RasGRP Ras guanine nucleotide exchange factors in cancer.

Olga Ksionda1, Andre Limnander1, Jeroen P Roose1.   

Abstract

RasGRP proteins are activators of Ras and other related small GTPases by the virtue of functioning as guanine nucleotide exchange factors (GEFs). In vertebrates, four RasGRP family members have been described. RasGRP-1 through -4 share many structural domains but there are also subtle differences between each of the different family members. Whereas SOS RasGEFs are ubiquitously expressed, RasGRP proteins are expressed in distinct patterns, such as in different cells of the hematopoietic system and in the brain. Most studies have concentrated on the role of RasGRP proteins in the development and function of immune cell types because of the predominant RasGRP expression profiles in these cells and the immune phenotypes of mice deficient for Rasgrp genes. However, more recent studies demonstrate that RasGRPs also play an important role in tumorigenesis. Examples are skin- and hematological-cancers but also solid malignancies such as melanoma or prostate cancer. These novel studies bring up many new and unanswered questions related to the molecular mechanism of RasGRP-driven oncogenesis, such as new receptor systems that RasGRP appears to respond to as well as regulatory mechanism for RasGRP expression that appear to be perturbed in these cancers. Here we will review some of the known aspects of RasGRP biology in lymphocytes and will discuss the exciting new notion that RasGRP Ras exchange factors play a role in oncogenesis downstream of various growth factor receptors.

Entities:  

Keywords:  Ras; RasGRP; cancer; lymphocytes; receptor; signaling

Year:  2013        PMID: 24744772      PMCID: PMC3987922          DOI: 10.1007/s11515-013-1276-9

Source DB:  PubMed          Journal:  Front Biol (Beijing)        ISSN: 1674-7984


  163 in total

1.  ERKs induce expression of the transcriptional repressor Blimp-1 and subsequent plasma cell differentiation.

Authors:  Tomoharu Yasuda; Kohei Kometani; Noriko Takahashi; Yuuki Imai; Yuichi Aiba; Tomohiro Kurosaki
Journal:  Sci Signal       Date:  2011-04-19       Impact factor: 8.192

2.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.

Authors:  Priscila P Zenatti; Daniel Ribeiro; Wenqing Li; Linda Zuurbier; Milene C Silva; Maddalena Paganin; Julia Tritapoe; Julie A Hixon; André B Silveira; Bruno A Cardoso; Leonor M Sarmento; Nádia Correia; Maria L Toribio; Jörg Kobarg; Martin Horstmann; Rob Pieters; Silvia R Brandalise; Adolfo A Ferrando; Jules P Meijerink; Scott K Durum; J Andrés Yunes; João T Barata
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

3.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

Review 4.  Prostate cancer and the met hepatocyte growth factor receptor.

Authors:  Beatrice S Knudsen; Magnus Edlund
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

5.  Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion.

Authors:  Tomoharu Yasuda; Hideki Sanjo; Gilles Pagès; Yohei Kawano; Hajime Karasuyama; Jacques Pouysségur; Masato Ogata; Tomohiro Kurosaki
Journal:  Immunity       Date:  2008-03-20       Impact factor: 31.745

Review 6.  Transitional B cells: step by step towards immune competence.

Authors:  James B Chung; Michael Silverman; John G Monroe
Journal:  Trends Immunol       Date:  2003-06       Impact factor: 16.687

7.  RasGRP1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis.

Authors:  Courtney T Luke; Carolyn E Oki-Idouchi; J Mark Cline; Patricia S Lorenzo
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

Review 8.  Biology and treatment of acute lymphoblastic leukemia.

Authors:  Rob Pieters; William L Carroll
Journal:  Pediatr Clin North Am       Date:  2008-02       Impact factor: 3.278

9.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

10.  Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Authors:  Jennifer O Lauchle; Doris Kim; Doan T Le; Keiko Akagi; Michael Crone; Kimberly Krisman; Kegan Warner; Jeannette M Bonifas; Qing Li; Kristen M Coakley; Ernesto Diaz-Flores; Matthew Gorman; Sally Przybranowski; Mary Tran; Scott C Kogan; Jeroen P Roose; Neal G Copeland; Nancy A Jenkins; Luis Parada; Linda Wolff; Judith Sebolt-Leopold; Kevin Shannon
Journal:  Nature       Date:  2009-09-02       Impact factor: 49.962

View more
  31 in total

1.  Flavors of EGFR-Ras signals impacting intestinal homeostasis.

Authors:  Philippe Depeille; Jeroen P Roose
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.

Authors:  Oghenekevwe M Gbenedio; Caroline Bonnans; Delphine Grun; Chih-Yang Wang; Ace J Hatch; Michelle R Mahoney; David Barras; Mary Matli; Yi Miao; K Christopher Garcia; Sabine Tejpar; Mauro Delorenzi; Alan P Venook; Andrew B Nixon; Robert S Warren; Jeroen P Roose; Philippe Depeille
Journal:  JCI Insight       Date:  2019-06-25

3.  RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.

Authors:  Philippe Depeille; Linda M Henricks; Robert A H van de Ven; Ed Lemmens; Chih-Yang Wang; Mary Matli; Zena Werb; Kevin M Haigis; David Donner; Robert Warren; Jeroen P Roose
Journal:  Nat Cell Biol       Date:  2015-05-25       Impact factor: 28.824

Review 4.  mTOR and other effector kinase signals that impact T cell function and activity.

Authors:  Darienne R Myers; Benjamin Wheeler; Jeroen P Roose
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

5.  Lost GRP on cytotoxicity?

Authors:  Jeroen P Roose
Journal:  Nat Immunol       Date:  2016-11-16       Impact factor: 25.606

6.  High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Authors:  Marsilius Mues; Laila Karra; Damia Romero-Moya; Anica Wandler; Matthew J Hangauer; Olga Ksionda; Yvonne Thus; Marthe Lindenbergh; Kevin Shannon; Michael T McManus; Jeroen P Roose
Journal:  Cell Rep       Date:  2019-04-09       Impact factor: 9.423

7.  RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.

Authors:  Xu Chen; Qiuxia Wu; Philippe Depeille; Peirong Chen; Sophie Thornton; Helen Kalirai; Sarah E Coupland; Jeroen P Roose; Boris C Bastian
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

8.  Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycle.

Authors:  Marsilius Mues; Jeroen P Roose
Journal:  Small GTPases       Date:  2016-05-09

Review 9.  8-Oxoguanine DNA glycosylase-1-driven DNA base excision repair: role in asthma pathogenesis.

Authors:  Xueqing Ba; Leopoldo Aguilera-Aguirre; Sanjiv Sur; Istvan Boldogh
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

Review 10.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.